Submit Deal

Submit Deal

Announced

2 Oct 2020

Completed

2 Nov 2020

Sartorius Stedim Biotech completed the acquisition of BIA Separations for $422m.

Synopsis

Sartorius Stedim Biotech, a partner of the biopharma industry, completed the acquisition of BIA Separations, a Slovenian biotech company, for $422m. "BIA's portfolio is highly complementary to Sartorius Stedim Biotech. We are thus creating an excellent offering for the manufacturing of gene therapies and other advanced therapies, and are pleased to welcome 120 new employees," Dr. Joachim Kreuzburg, Chairman of the Board and CEO Sartorius Stedim Biotech.

Principals

target

Bia Separations

bidder

Sartorius Stedim Biotech

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Dealmakers (33)

Service Providers

Sort

Ales Strancar

ManagerSEO and founder at BIA SEPARATIONS

Cory Kenny

Financial AdvisorManaging Director at EC M&A

Sebastian Lukic

LawyerAssociate at Schoenherr

Evan Yellin

Financial AdvisorManaging Director at EC M&A

Matthew Nicastro

Financial AdvisorVice President at EC M&A

Monika Bansal

Financial AdvisorManaging Director at EC M&A

Andreas Lengger

LawyerAssociate at Schoenherr

Thomas Kulnigg

LawyerPartner at Schoenherr

Han Wool Park

Financial AdvisorM&A Advisory at EC M&A

Jonathan Lee

Financial AdvisorAssociate at EC M&A

Raffaele Bonavitacola

Financial AdvisorDirector at EC M&A

Bojan Brezan

LawyerManaging Partner at Schoenherr

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.